$NERV
Minerva Neurosciences, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024091195 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.479M $2.417M
YoY Change -6.11% -8.18%
% of Gross Profit
Research & Development $1.888M $3.860M
YoY Change -45.18% 104.53%
% of Gross Profit
Depreciation & Amortization $5.620K $7.740K
YoY Change -43.8% 0.0%
% of Gross Profit
Operating Expenses $4.367M $6.278M
YoY Change -28.17% 38.88%
Operating Profit -$4.367M -$6.278M
YoY Change -28.17% 38.88%
Interest Expense $300.9K $356.1K
YoY Change -11.51% -0.66%
% of Operating Profit
Other Income/Expense, Net $26.58M -$2.312M
YoY Change -1377.84% 13.86%
Pretax Income $22.51M -$8.233M
YoY Change -387.89% 32.97%
Income Tax
% Of Pretax Income
Net Earnings $22.51M -$8.233M
YoY Change -387.88% 32.97%
Net Earnings / Revenue
Basic Earnings Per Share $2.97 -$1.09
Diluted Earnings Per Share $2.97 -$1.09
COMMON SHARES
Basic Shares Outstanding 6.993M 6.993M
Diluted Shares Outstanding 7.569M 7.569M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.53M $30.88M
YoY Change -43.44% -40.38%
Cash & Equivalents $26.53M $30.88M
Short-Term Investments
Other Short-Term Assets $1.407M $528.0K
YoY Change 8.26% 23.04%
Inventory
Prepaid Expenses $1.307M $428.0K
Receivables
Other Receivables
Total Short-Term Assets $27.94M $31.41M
YoY Change -42.07% -39.86%
LONG-TERM ASSETS
Property, Plant & Equipment $6.802K $8.163K
YoY Change -44.45% -40.02%
Goodwill $14.87M $14.87M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $14.88M $14.88M
YoY Change -0.19% -0.21%
TOTAL ASSETS
Total Short-Term Assets $27.94M $31.41M
Total Long-Term Assets $14.88M $14.88M
Total Assets $42.81M $46.29M
YoY Change -32.18% -31.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $553.2K $828.3K
YoY Change -60.35% 177.74%
Accrued Expenses $3.930M $3.375M
YoY Change 96.49% 109.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.483M $4.203M
YoY Change 33.84% 120.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $60.00M $86.58M
YoY Change -24.81% 11.37%
Total Long-Term Liabilities $60.00M $86.58M
YoY Change -24.81% 11.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.483M $4.203M
Total Long-Term Liabilities $60.00M $86.58M
Total Liabilities $64.48M $90.78M
YoY Change -22.47% 13.98%
SHAREHOLDERS EQUITY
Retained Earnings -$391.1M -$413.6M
YoY Change 0.85% 8.84%
Common Stock $369.4M $369.1M
YoY Change 0.46% 0.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$21.67M -$44.49M
YoY Change
Total Liabilities & Shareholders Equity $42.81M $46.29M
YoY Change -32.18% -31.05%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $22.51M -$8.233M
YoY Change -387.88% 32.97%
Depreciation, Depletion And Amortization $5.620K $7.740K
YoY Change -43.8% 0.0%
Cash From Operating Activities -$4.352M -$3.937M
YoY Change -9.33% 1.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -4.352M -3.937M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000
Net Change In Cash -4.352M -3.937M
YoY Change -11.0% -124.89%
FREE CASH FLOW
Cash From Operating Activities -$4.352M -$3.937M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001598646
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36517
dei Entity Registrant Name
EntityRegistrantName
Minerva Neurosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0784194
dei Entity Address Address Line1
EntityAddressAddressLine1
1500 District Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Burlington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01803
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
600-7373
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
NERV
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6993406
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30881000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40912575
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
428018
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
989865
CY2024Q2 us-gaap Assets Current
AssetsCurrent
31409018
CY2023Q4 us-gaap Assets Current
AssetsCurrent
42002440
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8163
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10884
CY2024Q2 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
4257
CY2023Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
17027
CY2024Q2 us-gaap Goodwill
Goodwill
14869399
CY2023Q4 us-gaap Goodwill
Goodwill
14869399
CY2024Q2 us-gaap Assets
Assets
46290837
CY2023Q4 us-gaap Assets
Assets
56899750
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
828345
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1805320
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3375061
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1535097
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4203406
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3340417
CY2024Q2 nerv Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
86579046
CY2023Q4 nerv Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
82016823
CY2024Q2 us-gaap Liabilities
Liabilities
90782452
CY2023Q4 us-gaap Liabilities
Liabilities
85357240
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6993406
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6993406
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6993406
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6993406
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
699
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
699
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
369125406
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
368357239
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-413617720
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396815428
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-44491615
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-28457490
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46290837
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56899750
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3860499
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1887476
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8027786
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4541029
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2417069
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2632519
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4931745
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5327484
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
6277568
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4519995
us-gaap Operating Expenses
OperatingExpenses
12959531
us-gaap Operating Expenses
OperatingExpenses
9868513
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6277568
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4519995
us-gaap Operating Income Loss
OperatingIncomeLoss
-12959531
us-gaap Operating Income Loss
OperatingIncomeLoss
-9868513
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4694
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7206
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
799
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-15892
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
360755
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
365623
us-gaap Investment Income Interest
InvestmentIncomeInterest
718663
us-gaap Investment Income Interest
InvestmentIncomeInterest
729841
CY2024Q2 nerv Non Cash Interest Expense For The Sale Of Future Royalties
NonCashInterestExpenseForTheSaleOfFutureRoyalties
2311980
CY2023Q2 nerv Non Cash Interest Expense For The Sale Of Future Royalties
NonCashInterestExpenseForTheSaleOfFutureRoyalties
2030458
nerv Non Cash Interest Expense For The Sale Of Future Royalties
NonCashInterestExpenseForTheSaleOfFutureRoyalties
4562223
nerv Non Cash Interest Expense For The Sale Of Future Royalties
NonCashInterestExpenseForTheSaleOfFutureRoyalties
4007884
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-8233487
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6192036
us-gaap Net Income Loss
NetIncomeLoss
-16802292
us-gaap Net Income Loss
NetIncomeLoss
-13162448
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.43
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7568981
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7568981
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5511163
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5511163
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7568981
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7568981
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5426150
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5426150
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-20024219
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
376459
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6970412
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-26618172
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19999994
CY2023Q2 nerv Adjustments To Additional Paid In Capital Costs Earnings Related To Stock And Warrants Issuance
AdjustmentsToAdditionalPaidInCapitalCostsEarningsRelatedToStockAndWarrantsIssuance
-309602
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
608915
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6192036
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-12510901
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-28457490
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
438849
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8568805
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-36587446
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
329318
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-8233487
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-44491615
us-gaap Profit Loss
ProfitLoss
-16802292
us-gaap Profit Loss
ProfitLoss
-13162448
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2721
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2721
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
12770
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
12770
us-gaap Share Based Compensation
ShareBasedCompensation
768167
us-gaap Share Based Compensation
ShareBasedCompensation
985374
nerv Non Cash Interest Expense For Sale Of Future Royalties
NonCashInterestExpenseForSaleOfFutureRoyalties
4562223
nerv Non Cash Interest Expense For Sale Of Future Royalties
NonCashInterestExpenseForSaleOfFutureRoyalties
4007884
us-gaap Increase Decrease In Regulatory Liabilities
IncreaseDecreaseInRegulatoryLiabilities
3117218
nerv Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
-561847
nerv Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
-518964
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-976975
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-671416
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1839964
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1201646
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10031575
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3987287
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
19999994
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
309602
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19690392
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10031575
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15703105
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41012575
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36193606
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30981000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51896711
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30881000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51796711
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30981000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51896711
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTE 1 — NATURE OF OPERATIONS AND LIQUIDITY</span></p><p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nature of Operations</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Minerva Neurosciences, Inc. (“Minerva” or the “Company”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system diseases. The Company’s lead product candidate is roluperidone, a compound the Company is developing for the treatment of negative symptoms in patients with schizophrenia. The Company previously submitted a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for roluperidone for the treatment of negative symptoms in schizophrenia in August 2022. On February 26, 2024, the FDA issued a Complete Response Letter regarding such NDA for roluperidone. Since receiving the Complete Response Letter, the Company has continued to have interactions with the FDA with the goal of addressing questions raised in such letter.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also has exclusive rights to develop and commercialize MIN-301, a compound for the treatment of Parkinson’s disease. In addition, Minerva previously co-developed seltorexant with Janssen Pharmaceutica NV (“Janssen”) for the treatment of insomnia disorder and adjunctive treatment of Major Depressive Disorder (“MDD”). During 2020, Minerva exercised its right to opt out of the joint development agreement with Janssen for the future development of seltorexant. As a result, the Company was entitled to collect royalties in the mid-single digits on potential future worldwide sales of seltorexant in certain indications, with no further financial obligations to Janssen. In January 2021, the Company sold its rights to these potential royalties to Royalty Pharma plc (“Royalty Pharma”) for a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million up front payment and up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in potential future milestone payments.</span></p><p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying interim condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations since inception. As of June 30, 2024, the Company had an accumulated deficit of approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">413.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and net cash used in operating activities was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the six months ended June 30, 2024. Management expects to continue to incur operating losses and negative cash flows from operations in the future. The Company has financed its operations to date from proceeds from the sale of common stock, warrants, loans, convertible promissory notes, collaboration agreements and royalty sales.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, the Company had cash, cash equivalents, and restricted cash of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which it believes will be sufficient to meet the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">’</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s operating commitments for the next 12 months from the date its financial statements are issued. The process of drug development can be costly and the timing and outcomes of clinical trials is uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company’s expenditures will vary depending upon many factors, including, but not limited to, the design, timing and duration of future clinical trials, the progress of the Company’s research and development programs, the infrastructure to support a commercial enterprise, and the level of financial resources available. The Company can adjust its operating plan spending levels based on the timing of future clinical trials, which are predicated upon adequate funding to complete the trials. The Company routinely evaluates the status of its clinical development programs as well as potential strategic options.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will need to raise additional capital to continue to fund operations and fully fund any potential later stage clinical development programs. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund future operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if the Company does not satisfy The Nasdaq Capital Market continued listing requirements, its common stock may be subject to delisting, which could impact the Company’s ability to complete additional equity financings on terms acceptable to the Company. On April 10, 2024, the Company received a deficiency letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 31 consecutive business days, the market value of listed securities (“MVLS requirement”) for its common stock had been below the minimum MVLS requirement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pursuant to Nasdaq Listing Rule 5550(b)(2). In accordance with the listing rules of Nasdaq, the Company has been provided with a grace period of 180 calendar days, or until October 7, 2024, to regain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company does not regain compliance within the grace period, the Company expects that Nasdaq would provide notice that its securities are subject to delisting.</span></p>
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-413600000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10000000
CY2024Q2 nerv Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
31000000
CY2024Q2 nerv Minimum Market Value Of Listed Securities Required For Continued Listing
MinimumMarketValueOfListedSecuritiesRequiredForContinuedListing
35000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p>
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2024Q2 nerv Accrued Research And Development Costs And Other Expenses Current
AccruedResearchAndDevelopmentCostsAndOtherExpensesCurrent
1964147
CY2023Q4 nerv Accrued Research And Development Costs And Other Expenses Current
AccruedResearchAndDevelopmentCostsAndOtherExpensesCurrent
777680
CY2024Q2 nerv Accrued Severance Current
AccruedSeveranceCurrent
245387
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
727302
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
590769
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
381775
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
166648
CY2024Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
56450
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3375061
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1535097
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-8233487
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6192036
us-gaap Net Income Loss
NetIncomeLoss
-16802292
us-gaap Net Income Loss
NetIncomeLoss
-13162448
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7568981
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7568981
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5511163
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5511163
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7568981
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7568981
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5426150
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5426150
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.43
CY2021Q1 nerv Liability Related To The Sale Of Future Royalties
LiabilityRelatedToTheSaleOfFutureRoyalties
60000000
CY2021Q1 nerv Annual Interest Rate On Interest Expense
AnnualInterestRateOnInterestExpense
0.105
CY2024Q2 nerv Annual Interest Rate On Interest Expense
AnnualInterestRateOnInterestExpense
0.1097
nerv Upfront Payment Paid
UpfrontPaymentPaid
60000000
nerv Non Cash Interest Expense For Sale Of Future Royalties
NonCashInterestExpenseForSaleOfFutureRoyalties
26579046
CY2024Q2 nerv Liability Related To The Sale Of Future Royalties
LiabilityRelatedToTheSaleOfFutureRoyalties
86579046
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
329318
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
608915
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
768167
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
985374

Files In Submission

Name View Source Status
0000950170-24-091195-index-headers.html Edgar Link pending
0000950170-24-091195-index.html Edgar Link pending
0000950170-24-091195.txt Edgar Link pending
0000950170-24-091195-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nerv-20240630.htm Edgar Link pending
nerv-20240630.xsd Edgar Link pending
nerv-ex31_1.htm Edgar Link pending
nerv-ex31_2.htm Edgar Link pending
nerv-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nerv-20240630_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending